

## IP FOLFIRI / PANITUMUMAB

**Types:** ONCOLOGY TREATMENT

**Synonyms:** FOLFIRI, IRINOTECAN, LEUCOVORIN, 5FU, 5-FLUOROURACIL, FLUOROURACIL, LEUCO, IRIN, CAMPTOSAR, CAMP, CET, PANITUMUMAB, PANT, VECTIBEX, VEX, COLORECTAL, GI

|                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|-----------------------|---------------------|-----------------|------------------|-------------|-----------------|------------------|--|---------------------------------------------------|-------------|-------|-----|----|--|------------------------------------------|-------------|-------|-----|----|
| Cycle 1                                                                                                                                                                                                                                                                                                                                                                                                                            | Repeat 1 time                                     | Cycle length: 14 days |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| Day 1                                                                                                                                                                                                                                                                                                                                                                                                                              | Perform every 1 day x1                            |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| Provider Communication                                                                                                                                                                                                                                                                                                                                                                                                             |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| <b>ONC PROVIDER COMMUNICATION 2</b><br>Interval: Once                      Occurrences: --<br>Comments:                      Tumor KRAS gene status should be determined prior to initiation of therapy.    KRAS type: Please Push F2:115540219.                                                                                                                                                                                   |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| Labs                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| <input checked="" type="checkbox"/> <b>COMPREHENSIVE METABOLIC PANEL</b><br>Interval: Once                      Occurrences: --                                                                                                                                                                                                                                                                                                    |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| <input checked="" type="checkbox"/> <b>CBC WITH PLATELET AND DIFFERENTIAL</b><br>Interval: Once                      Occurrences: --                                                                                                                                                                                                                                                                                               |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| <input checked="" type="checkbox"/> <b>MAGNESIUM LEVEL</b><br>Interval: Once                      Occurrences: --                                                                                                                                                                                                                                                                                                                  |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| Nursing Orders                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| <b>TREATMENT CONDITIONS 4</b><br>Interval: Until discontinued                      Occurrences: --<br>Comments:                      HOLD and notify provider if ANC LESS than 1000; Platelets LESS than 100,000; Total Bilirubin GREATER than 1.5; ALT/AST GREATER than 3 times upper normal limit; or Serum Creatinine GREATER than 1.2                                                                                          |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| Line Flush                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| <b>sodium chloride 0.9 % flush 20 mL</b><br>Dose: 20 mL                      Route: intravenous                      PRN<br>Start: S                                                                                                                                                                                                                                                                                               |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| Nursing Orders                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| <b>sodium chloride 0.9 % infusion 250 mL</b><br>Dose: 250 mL                      Route: intravenous                      once @ 30 mL/hr for 1 dose<br>Start: S<br>Instructions:                      To keep vein open.                                                                                                                                                                                                          |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| Pre-Medications                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| <b>ondansetron (ZOFRAN) 16 mg, dexamethasone (DECADRON) 12 mg in sodium chloride 0.9% 50 mL IVPB</b><br>Dose: --                      Route: intravenous                      once over 15 Minutes for 1 dose<br>Start: S                      End: S 11:30 AM                                                                                                                                                                     |                                                   |                       |                     |                 |                  |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
| <table><tr><td><b>Ingredients:</b></td><td><b>Name</b></td><td><b>Type</b></td><td><b>Dose</b></td><td><b>Selected</b></td><td><b>Adds Vol.</b></td></tr><tr><td></td><td>ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION</td><td>Medications</td><td>16 mg</td><td>Yes</td><td>No</td></tr><tr><td></td><td>DEXAMETHASONE 4 MG/ML INJECTION SOLUTION</td><td>Medications</td><td>12 mg</td><td>Yes</td><td>No</td></tr></table> |                                                   |                       | <b>Ingredients:</b> | <b>Name</b>     | <b>Type</b>      | <b>Dose</b> | <b>Selected</b> | <b>Adds Vol.</b> |  | ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION | Medications | 16 mg | Yes | No |  | DEXAMETHASONE 4 MG/ML INJECTION SOLUTION | Medications | 12 mg | Yes | No |
| <b>Ingredients:</b>                                                                                                                                                                                                                                                                                                                                                                                                                | <b>Name</b>                                       | <b>Type</b>           | <b>Dose</b>         | <b>Selected</b> | <b>Adds Vol.</b> |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    | ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION | Medications           | 16 mg               | Yes             | No               |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    | DEXAMETHASONE 4 MG/ML INJECTION SOLUTION          | Medications           | 12 mg               | Yes             | No               |             |                 |                  |  |                                                   |             |       |     |    |  |                                          |             |       |     |    |

|                     |  |  |                                                                                                   |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|---------------------|--|--|---------------------------------------------------------------------------------------------------|-------------|--------------------|-----------------|---------------------------------|-------|--------|-----|--|--|--|--|--|--|
|                     |  |  | SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION                                                        |             |                    |                 | Base                            | 50 mL | Always | Yes |  |  |  |  |  |  |
|                     |  |  | DEXTROSE 5 % IN WATER (D5W) INTRAVENOUS SOLUTION                                                  |             |                    |                 | Base                            |       | No     | Yes |  |  |  |  |  |  |
|                     |  |  | <input type="checkbox"/> <b>ondansetron (ZOFTRAN) tablet 16 mg</b>                                |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | Dose: 16 mg                                                                                       |             | Route: oral        |                 | once for 1 dose                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | Start: S                                                                                          |             | End: S 11:30 AM    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | <input type="checkbox"/> <b>dexamethasone (DECADRON) tablet 12 mg</b>                             |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | Dose: 12 mg                                                                                       |             | Route: oral        |                 | once for 1 dose                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | Start: S                                                                                          |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | <input type="checkbox"/> <b>aprepitant (CINVANTI) 130 mg in dextrose (NON-PVC) 5% 130 mL IVPB</b> |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | Dose: 130 mg                                                                                      |             | Route: intravenous |                 | once over 30 Minutes for 1 dose |       |        |     |  |  |  |  |  |  |
|                     |  |  | Start: S                                                                                          |             | End: S             |                 |                                 |       |        |     |  |  |  |  |  |  |
| <b>Ingredients:</b> |  |  | <b>Name</b>                                                                                       | <b>Type</b> | <b>Dose</b>        | <b>Selected</b> | <b>Adds Vol.</b>                |       |        |     |  |  |  |  |  |  |
|                     |  |  | APREPITANT 7.2 MG/ML                                                                              | Medications | 130 mg             | Main Ingredient | Yes                             |       |        |     |  |  |  |  |  |  |
|                     |  |  | INTRAVENOUS EMULSION                                                                              |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | DEXTROSE 5 % IN WATER (D5W) IV SOLP (EXCEL; NON-PVC)                                              | Base        | 130 mL             | Yes             | Yes                             |       |        |     |  |  |  |  |  |  |
|                     |  |  | SODIUM CHLORIDE 0.9 % IV SOLP (EXCEL;NON-PVC)                                                     | Base        | 130 mL             | No              | Yes                             |       |        |     |  |  |  |  |  |  |
| Pre-Medications     |  |  |                                                                                                   |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | <b>atropine injection 0.25 mg</b>                                                                 |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | Dose: 0.25 mg                                                                                     |             | Route: intravenous |                 | PRN                             |       |        |     |  |  |  |  |  |  |
|                     |  |  | Start: S                                                                                          |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  |                                                                                                   |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
| Supportive Care     |  |  |                                                                                                   |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | <input type="radio"/> <b>LORAZepam (ATIVAN) injection 1 mg</b>                                    |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | Dose: 1 mg                                                                                        |             | Route: intravenous |                 | PRN                             |       |        |     |  |  |  |  |  |  |
|                     |  |  | Start: S                                                                                          |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | <input type="radio"/> <b>LORAZepam (ATIVAN) tablet 1 mg</b>                                       |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | Dose: 1 mg                                                                                        |             | Route: oral        |                 | PRN                             |       |        |     |  |  |  |  |  |  |
|                     |  |  | Start: S                                                                                          |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
| Chemotherapy        |  |  |                                                                                                   |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | <b>panitumumab (VECTIBIX) 6 mg/kg in sodium chloride 0.9 % 100 mL chemo IVPB</b>                  |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | Dose: 6 mg/kg                                                                                     |             | Route: intravenous |                 | once over 60 Minutes for 1 dose |       |        |     |  |  |  |  |  |  |
|                     |  |  |                                                                                                   |             |                    |                 | Offset: 30 Minutes              |       |        |     |  |  |  |  |  |  |
|                     |  |  | Instructions:<br>USE 0.2 OR 0.22 MICRON INLINE FILTER.                                            |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  |                                                                                                   |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
| <b>Ingredients:</b> |  |  | <b>Name</b>                                                                                       | <b>Type</b> | <b>Dose</b>        | <b>Selected</b> | <b>Adds Vol.</b>                |       |        |     |  |  |  |  |  |  |
|                     |  |  | PANITUMUMAB 100 MG/5 ML (20 MG/ML)                                                                | Medications | 6 mg/kg            | Main Ingredient | Yes                             |       |        |     |  |  |  |  |  |  |
|                     |  |  | INTRAVENOUS SOLUTION                                                                              |             |                    |                 |                                 |       |        |     |  |  |  |  |  |  |
|                     |  |  | SODIUM                                                                                            | QS Base     | 100 mL             | Yes             | Yes                             |       |        |     |  |  |  |  |  |  |

CHLORIDE 0.9 %  
INTRAVENOUS  
SOLUTION

**leucovorin 400 mg/m2 in sodium chloride 0.9 %  
250 mL chemo IVPB**

Dose: 400 mg/m2

Route: intravenous

once over 90 Minutes for 1 dose

Offset: 1.5 Hours

**Ingredients:**

**Name**

**Type**

**Dose**

**Selected**

**Adds Vol.**

LEUCOVORIN  
CALCIUM 350 MG  
SOLUTION FOR  
INJECTION

Medications

400  
mg/m2

Main

Yes

Ingredient

DEXTROSE 5 % IN  
WATER (D5W)  
INTRAVENOUS  
SOLUTION

QS Base

250 mL

No

Yes

SODIUM  
CHLORIDE 0.9 %  
INTRAVENOUS  
SOLUTION

QS Base

250 mL

Yes

Yes

**irinotecan (CAMPTOSAR) 180 mg/m2 in  
dextrose 5% 500 mL chemo IVPB**

Dose: 180 mg/m2

Route: intravenous

once over 90 Minutes for 1 dose

Offset: 1.5 Hours

**Instructions:**

Protect from light

**Ingredients:**

**Name**

**Type**

**Dose**

**Selected**

**Adds Vol.**

IRINOTECAN 100  
MG/5 ML  
INTRAVENOUS  
SOLUTION

Medications

180  
mg/m2

Main

Yes

Ingredient

DEXTROSE 5 % IN  
WATER (D5W)  
INTRAVENOUS  
SOLUTION

QS Base

500 mL

Yes

Yes

SODIUM  
CHLORIDE 0.9 %  
INTRAVENOUS  
SOLUTION

QS Base

500 mL

No

Yes

**fluorouracil (ADRUCIL) 400 mg/m2 in sodium  
chloride 0.9 % 50 mL chemo IVPB**

Dose: 400 mg/m2

Route: intravenous

once over 15 Minutes for 1 dose

Offset: 3 Hours

**Ingredients:**

**Name**

**Type**

**Dose**

**Selected**

**Adds Vol.**

FLUOROURACIL 5  
GRAM/100 ML  
INTRAVENOUS  
SOLUTION

Medications

400  
mg/m2

Main

Yes

Ingredient

DEXTROSE 5 % IN  
WATER (D5W)  
INTRAVENOUS  
SOLUTION

QS Base

No

Yes

SODIUM  
CHLORIDE 0.9 %  
INTRAVENOUS  
SOLUTION

QS Base

50 mL

Yes

Yes

**fluorouracil (ADRUCIL) 1,200 mg/m2 in sodium  
chloride 0.9 % 500 mL chemo IVPB**

Dose: 1,200 mg/m2

Route: intravenous

once over 23 Hours for 1 dose

Offset: 3.25 Hours

**Inaredients:**

**Name**

**Tvpe**

**Dose**

**Selected**

**Adds Vol.**

|                                                           |             |                |                    |     |
|-----------------------------------------------------------|-------------|----------------|--------------------|-----|
| FLUOROURACIL<br>500 MG/10 ML<br>INTRAVENOUS<br>SOLUTION   | Medications | 1,200<br>mg/m2 | Main<br>Ingredient | Yes |
| DEXTROSE 5 % IN<br>WATER (D5W)<br>INTRAVENOUS<br>SOLUTION | QS Base     | 500 mL         | No                 | Yes |
| SODIUM<br>CHLORIDE 0.9 %<br>INTRAVENOUS<br>SOLUTION       | QS Base     | 500 mL         | Yes                | Yes |

#### Hematology & Oncology Hypersensitivity Reaction Standing Order

##### **ONC NURSING COMMUNICATION 82**

Interval: Until  
discontinued

Occurrences: --

Comments:

Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms only – itching, flushing, periorbital edema, rash, or runny nose)

1. Stop the infusion.
2. Place the patient on continuous monitoring.
3. Obtain vital signs.
4. Administer Normal Saline at 50 mL per hour using a new bag and new intravenous tubing.
5. If greater than or equal to 30 minutes since the last dose of Diphenhydramine, administer Diphenhydramine 25 mg intravenous once.
6. If less than 30 minutes since the last dose of Diphenhydramine, administer Fexofenadine 180 mg orally and Famotidine 20 mg intravenous once.
7. Notify the treating physician.
8. If no improvement after 15 minutes, advance level of care to Grade 2 (Moderate) or Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

##### **ONC NURSING COMMUNICATION 83**

Interval: Until  
discontinued

Occurrences: --

Comments:

Grade 2 – MODERATE Symptoms (cardiovascular, respiratory, or gastrointestinal symptoms – shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)

1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Fexofenadine 180 mg orally and Famotidine 20 mg intravenous once.
8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

##### **ONC NURSING COMMUNICATION 4**

Interval: Until

Occurrences: --

discontinued  
Comments:

Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O2 saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)

1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O2 saturation of greater than or equal to 92%.
7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

**diphenhydramine (BENADRYL) injection 25 mg**

Dose: 25 mg                      Route: intravenous                      PRN  
Start: S

**fexofenadine (ALLEGRA) tablet 180 mg**

Dose: 180 mg                      Route: oral                      PRN  
Start: S

**famotidine (PEPCID) 20 mg/2 mL injection 20 mg**

Dose: 20 mg                      Route: intravenous                      PRN  
Start: S

**hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg**

Dose: 100 mg                      Route: intravenous                      PRN

**dexamethasone (DECADRON) injection 4 mg**

Dose: 4 mg                      Route: intravenous                      PRN  
Start: S

**epINEPHrine (ADRENALIN) 1 mg/10 mL ADULT injection syringe 0.3 mg**

Dose: 0.3 mg                      Route: subcutaneous                      PRN  
Start: S

**Nursing Orders**

**ONC NURSING COMMUNICATION 14**

Interval: Until                      Occurrences: --  
discontinued

Comments:                      Contact Provider if drug-induced acneiform rash develops and covers more than 25 per cent of the body.

**Discharge Nursing Orders**

☒ **sodium chloride 0.9 % flush 20 mL**

Dose: 20 mL                      Route: intravenous                      PRN

☒ **HEParin, porcine (PF) injection 500 Units**

Dose: 500 Units                      Route: intra-catheter                      once PRN  
Start: S

Instructions:  
Concentration: 100 units/mL. Heparin flush for  
Implanted Vascular Access Device  
maintenance.

## Day 2

Perform every 1 day x1

### Nursing Orders

#### **sodium chloride 0.9 % infusion 250 mL**

Dose: 250 mL

Route: intravenous

once @ 30 mL/hr for 1 dose

Start: S

Instructions:

To keep vein open.

### Pre-Medications

#### **ondansetron (ZOFTRAN) 16 mg in sodium chloride 0.9 % 50 mL IVPB**

Dose: --

Route: intravenous

once over 15 Minutes for 1 dose

Start: S

End: S 10:00 AM

#### **Ingredients:**

#### **Name**

#### **Type**

#### **Dose**

#### **Selected**

#### **Adds Vol.**

ONDANSETRON  
HCL (PF) 4 MG/2  
ML INJECTION  
SOLUTION

Medications

16 mg

Yes

No

DEXAMETHASONE  
4 MG/ML  
INJECTION  
SOLUTION

Medications

12 mg

No

No

SODIUM  
CHLORIDE 0.9 %  
INTRAVENOUS  
SOLUTION  
DEXTROSE 5 % IN  
WATER (D5W)  
INTRAVENOUS  
SOLUTION

Base

50 mL

Always

Yes

Base

No

Yes

### Chemotherapy

#### **fluorouracil (ADRUCIL) 1,200 mg/m2 in sodium chloride 0.9 % 500 mL chemo IVPB**

Dose: 1,200 mg/m2

Route: intravenous

once over 23 Hours for 1 dose

#### **Ingredients:**

#### **Name**

#### **Type**

#### **Dose**

#### **Selected**

#### **Adds Vol.**

FLUOROURACIL  
500 MG/10 ML  
INTRAVENOUS  
SOLUTION

Medications

1,200  
mg/m2

Main  
Ingredient

Yes

DEXTROSE 5 % IN  
WATER (D5W)  
INTRAVENOUS  
SOLUTION

QS Base

500 mL

No

Yes

SODIUM  
CHLORIDE 0.9 %  
INTRAVENOUS  
SOLUTION

QS Base

500 mL

Yes

Yes